Introduction/Background To evaluate the morbidity of perioperative total parietal peritonectomy (TPP) during cytoreduction surgery (CRS), and its impact on the site of recurrence of different peritoneal surface malignancies (PSM).

Methodology We led a retrospective study in a French tertiary cancer institution (Centre Oscar Lambret - Lille) experienced in treating PSM over a 6-year period from 2012 to 2018. All patients underwent a total parietal peritonectomy during a debulking surgery for PSM including ovarian cancer, appendiceal pseudomyxoma peritonei or peritoneal mesothelioma.

Results Sixty-one patients were included in this study with 79% of them having ovarian cancer. The rate of optimal surgery reached 87% with almost 70% of surgeries being highly complicated. 74.2% were transfused during the surgical procedure. The median hospitalization stay was 10 days including 7 days in Intensive Care Unit (ICU). 30% had early postoperative complications with no grade 4 and 42% Grade 3 complications. After a 30-months median follow-up, 84% of ovarian cancer group had no recurrence of the disease the first year and a 3-year survival of 77%. The main site of first and second recurrence was peritoneal (51% and 56.3%). In this series, there have been no cases of metastatic evolution of the abdominal wall.

Conclusion TPP is a feasible surgical procedure to treat peritoneal surface malignancies and their recurrences with a low rate of Grade 3–4 morbidity. Even though, TPP doesn’t prevent peritoneal recurrence, it allow optimal surgery.

Disclosure Nothing to disclose